Loading...
•
Sep 30
Nuwellis Q3 2025 Earnings Report
Nuwellis reported Q3 2025 results with a return to profitability and a focus on expanding U.S. operations.
Key Takeaways
Nuwellis posted a net income in Q3 2025, supported by increased U.S. console sales and consumable utilization. Despite a slight year-over-year revenue decline, operational progress and product launches supported a strong sequential recovery.
Revenue for Q3 2025 was $2.2 million, up 29% sequentially but down 6% YoY.
Net income reached $468,000, marking a return to profitability.
Gross margin declined to 65.2% due to unfavorable manufacturing utilization.
Raised $1.9 million through ATM facility; ended the quarter with $3.1 million in cash.
Nuwellis
Nuwellis
Forward Guidance
Nuwellis plans to concentrate on U.S. market growth while accelerating pediatric innovation and outpatient therapy expansion.
Positive Outlook
- First Aquadex therapies delivered in hospital-based outpatient setting
- U.S. launch of 24-hour circuit and dual-lumen catheter
- Pediatric development supported by NIH collaboration and patent issuance
- Increased U.S. console sales and consumable utilization
- Raised $1.9M in funding to support operations
Challenges Ahead
- Year-over-year revenue declined by 6%
- Gross margin decreased to 65.2% from 70.0%
- Operating loss widened to $2.7 million
- Continued exit from international operations
- R&D and SG&A expenses increased, impacting profitability